Objective: Preliminary evidence suggests that serotonin reuptake inhibitor (SRI) use may increase postictal respiratory drive and prevent death. We sought to determine whether SRIs are associated with improved all-cause and possible seizure-specific mortality in patients with epilepsy. Methods: Patients with epilepsy and a random 10:1 sample without epilepsy were extracted from The ClinicAl research using LInked Bespoke studies and Electronic health Records (CALIBER) resource. The hazard ratio (HR) of all-cause and possible seizure-specific mortality, treating SRI use as a time-varying covariate, was determined using the date of a second SRI prescription as exposure and in discrete 6-month periods over the entire duration of follow-up. We used Cox regression and competing risk models with Firth correction to calculate the HR. We controlled for age, sex, depression, comorbidity, (Charlson comorbidity index) and socioeconomic status (Index of Multiple Deprivation). Results: We identified 2,718,952 eligible patients in CALIBER, of whom 16,379 (0.60%) had epilepsy. Median age and follow-up were 44 (interquartile range [IQR] 29-61]) and 6.4 years (IQR 2.4-10.4 years), respectively, and 53% were female. A total of 2,178 patients (13%) had at least two SRI prescriptions. Hazard of all-cause mortality was significantly elevated following a second prescription for an SRI (HR 1.64 95% confidence interval [95% CI] 1.44-1.86; p < 0.001). The HR was similar in 163,778 age, sex, and general practitioner (GP) practice-matched controls without epilepsy. Exposure to an SRI was not associated with seizure-related death (HR 1.08, 95% CI 0.59-1.97; 0.796). Significance: There is no evidence in this large population-based cohort that SRIs protect against all-cause mortality or seizure-specific mortality. Rather, SRI use was associated with increased mortality, irrespective of epilepsy, which is probably due to various factors associated with the use of antidepressants. Larger studies with systematically collected clinical data are needed to shed further light on these findings.
Premature mortality in epilepsy is a major concern facing general practitioners, neurologists, and epileptologists alike. The estimated standardized mortality ratio (SMR) for persons with epilepsy is 2.2-fold higher than that for people without epilepsy. 1 Hence, interventions designed to reduce all-cause premature mortality are of intense interest.
In addition, sudden unexpected death in epilepsy (SUDEP) is a specific cause of death and a major health concern for people with epilepsy. It is defined as a sudden, unexpected, nontraumatic, and nondrowning death of a patient with epilepsy with no postmortem evidence of a structural or toxicologic cause for death. 2 Based on this working definition, sudden unexpected death is almost 24 times more likely in selected populations with epilepsy compared to the general population SMR 23.7, 95% confidence interval [95% CI] 7.7 to 55.0). 3 Estimates of SUDEP incidence range from 0.09 to 9.3 per 1,000 person-years depending on the severity of epilepsy. 4 The pathologic processes leading to seizure-related deaths and, specifically to SUDEP, remain elusive. Postictal respiratory depression, cardiac arrhythmias, and electrocerebral suppression may contribute to the increased risk of death. 4, 5 Serotonin reuptake inhibitors (SRIs) may have particular promise as a therapeutic intervention because they increase mental vigilance, promote respiratory activity, and may prevent sudden death. 6 Reductions in ictal respiratory arrest with SRIs and increased respiratory depression with the serotonin antagonist cyproheptadine have been demonstrated using murine models. 7, 8 Furthermore, a reduction in ictal-related oxygen desaturations in focal seizures without bilateral convulsions has been reported in patients taking SRIs admitted to seizure monitoring units. 9 There has therefore been interest in exploring the therapeutic role of SRIs as a means of reducing premature mortality, especially for patients at high risk of SUDEP. 10 However, to date, no large-scale studies in humans have been performed to either confirm or refute this potential indication. We carried out an observational study using large, preexisting linked primary care data in England collected during routine clinical practice to examine the association between SRI use and mortality in patients with epilepsy.
Methods
The ClinicAl research using LInked Bespoke studies and Electronic health Records (CALIBER) resource (https://www.ucl.ac.uk/health-informatics/caliber) 11 contains United Kingdom (UK) nationally linked structured electronic health record (EHR) data from primary care, hospital care, and a cause-specific mortality registry between January 1, 1997 and March 31, 2010. We only followed patients enrolled from January 1, 1997 to March 31, 2009 to account for an up to 1-year lag in mortality reporting.
The platform contains pseudonymized health records of 2,718,952 eligible adult patients. Primary care diagnostic data are recorded using Read codes. 12 Prescription data are recorded by the general practitioner and classified according to the British National Formulary. 13, 14 Audit nurses and professional clinical coders are employed to abstract secondary care and administrative data into the Hospital Episode Statistics database. Diagnoses and procedures coded in the affiliated databases use the International Classification of Diseases (ICD) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures terminology. Cause-specific mortality data are acquired from death certificates and categorized using the ICD-9 and ICD-10 terminologies at the UK Office for National Statistics.
Study population
We used a published epilepsy case definition designed specifically for Clinical Practice Research Datalink (CPRD) electronic health record (EHR) platforms. 15 This definition requires a single Read code for an epilepsy syndrome or two Read codes for symptoms of epilepsy (i.e., codes for nonfebrile seizures on two or more occasions) and two antiepileptic drug codes within 4 months. The definition is 92% accurate for detecting cases of pediatric epilepsy 15 and, after review by two adult epileptologists (CBJ and SW), is expected to perform comparably well in adult populations. We ultimately compared the prevalence to that of the UK population as a means of establishing face validity of the epilepsy cohort. 16 All patients aged 18 years or older at epilepsy diagnosis, registered in CPRD practices in England, with at least 1 year of up-to-standard pre-study follow-up during which the patient was not prescribed an SRI (paroxetine, fluoxetine, fluvoxamine, sertraline, citalopram, and escitalopram) were included in the analysis. The up-to-standard designation is provided by CPRD following regular quality
Key points
• Serotonin reuptake inhibitors have been associated with increased respiratory drive in the postictal state
• Clinical need for a serotonin reuptake inhibitor is associated with increased all-cause mortality in patients with and without epilepsy
• Clinical need for a serotonin reuptake inhibitor is not associated with seizure-related mortality in this large population-based cohort
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• Randomized controlled trials of serotonin reuptake inhibitor use for mortality in epilepsy are impractical; linked electronic health data provide an alternative checks and practices in each general practitioner (GP) surgery. The date the criteria are met is the up-to-standard date.
Statistical analysis
The index date was that on which the patient met the case definition for epilepsy. The index date was 1-year post up-to-standard date in those without epilepsy (who were matched on age, sex, and GP practice). Parametric and nonparametric descriptive statistics were used to compare populations of interest. We calculated mortality incidence rates for the epilepsy and control populations as a whole and stratified by SRI use.
Multiple independent analyses were used to evaluate the association between SRI use and mortality. First, we treated SRI prescriptions as time-varying covariates. To exclude trivial exposures, a patient was considered unexposed until their second SRI prescription. On this date, their status transitioned from unexposed to exposed, and they maintained this designation until the end of follow-up.
We cannot ensure an enduring exposure through this approach and therefore, to mitigate this concern, we performed a second time-varying Cox-proportional hazards regression analysis in which we stratified follow-up into discrete 6-month epochs to more firmly establish any temporal association between SRI prescription and death. In this time-varying analysis, exposure to an SRI prescription was recorded as a dichotomous ("yes"/"no") variable during each epoch, based on the presence or absence of a prescription code during that time period. We then coded each patient as having lived ("0") or died ("1") during that same epoch.
The primary outcome was all-cause mortality. The secondary outcome was possible seizure-related death (under which SUDEP would fall) as defined by selected ICD-10 codes from epilepsy/seizures/convulsions, unknown/unspecified death, and sudden death diagnostic categories (Appendix S1). In addition to time-varying SRI status, we also controlled for baseline age, sex, past or current depression (using an electronic health records phenotype defined in a prior CALIBER study 17 ), comorbidity using the Charlson comorbidity index (CCI), and for socioeconomic status with the Index of Multiple Deprivation (IMD), a measure of relative deprivation in 32,844 localized regions of England (1 being the most deprived and 32,844 being the least deprived). 18 In a separate analysis, we also included an interaction term between sex and second SRI prescription exposure to investigate any putative sex-specific effect. In each analysis, patients were censored at the end of the follow-up if no outcome occurred or they were lost to follow-up.
We considered a p-value of ≤0.05 to be statistically significant. We used cause-specific Cox regression and the Fine and Gray competing risks models 19 that used a Firth penalized likelihood method 20 to account for the rarity of seizure-related deaths in this sample.
Sensitivity analyses
We randomly identified exact age, sex, and GP practicematched control patients without epilepsy in a 10:1 ratio using MySQL 5.7. 21 The algorithm identifies potential matches and orders them randomly by assigning a random seed. Checks are then instituted to ensure minimum followup, concordant observation periods, and up-to-standard data. All analyses were replicated in this control cohort to determine if the association between SRI use and mortality is unique to patients with epilepsy or common to the general population.
Finally, we performed a sensitivity analysis in which we evaluated the risk of all-cause death and possible seizurerelated death, using the analysis plan described earlier, following a second prescription for bupropion. This is a unique antidepressant that does not modulate the serotonin system. Thus we aimed to determine whether any putative association between prescription coding and death was serotonin specific or related to antidepressant use in general.
Software
All analyses were conducted using Stata version 13.1,
22
R, 23 and SAS software. 
Results
We identified 2,718,952 patients in CALIBER of whom 16,379 (0.60%) met the case definition for epilepsy. Median age was 44 years (interquartile range [IQR] 29-61) and 8,610 (53%) were female. Median follow-up was 6.4 years (IQR 2.4-10.4 years). For basic descriptive statistics, we considered exposure to two or more SRI prescriptions as meaningful. According to this definition, 2,178 patients with epilepsy (13%) received an SRI. Patients receiving two SRI prescriptions differed from those receiving one or no prescription on a number of demographic indices in directions anticipated from clinical experience ( Table 1) .
SRI exposure and all-cause mortality
The unadjusted incidence rate of all-cause mortality was approximately twofold higher for those with epilepsy (n = 16,379; incidence rate = 0.024 [2,524 deaths/ 105644.1 person-years]) compared to those without (n = 163, 778; incidence rate = 0.012 [14, Exposure to a second SRI prescription was associated with an increased hazard of death (hazard ratio [HR] 1.64, 95% CI 1.44-1.86; p < 0.001) in persons with epilepsy. Additional associations with all-cause death were noted for age (HR 1.06 for each increment in age, 95% CI 1.06-1.07), female sex (HR 0.78, 95% CI 0.72-0.85; p < 0.001), and MD score (HR 1.01, 95% CI 1.01-1.01; p < 0.001; Table 2 , Fig. 1 ). There was no sex-specific effect of a second SRI prescription on premature mortality when an interaction term was included in the regression model (sex by SRI prescription HR = 0.87, 95% CI 0.69-1.10; p = 0.252).
Exposure to a single SRI prescription was associated with a statistically significant increased hazard of death within 6 months (hazard ratio [HR] 1.04, 95%CI 1.00-1.09, p = 0.04; Table 3 ) when controlling for age, sex, CCI, IMD, and depression in those with epilepsy. In addition, the hazard of death was elevated for each 1-year increment in age (HR 1.06, 95% CI 1.06-1.07; p < 0.001), and each incremental one-rank increase in social deprivation (HR 1.01, 1.01-1.01; p < 0.001). Female sex was protective (HR 0.76, 95% CI 0.70-0.83; p < 0.001; Table 3 ).
The hazard ratio of all-cause death was similarly elevated for 163,778 age, sex, and GP practice matched controls without epilepsy. Those exposed to a second SRI prescription had an increased risk of all-cause death (HR 2.07, 95% CI 1.95-2.20; p < 0.001; Table S1 ) when controlling for age, sex, depression, CCI, and IMD. Increasing age (HR 1.10 for each incremental year, 95% CI 1.09-1.10; p < 0.001) and increasing social deprivation (HR 1.01, 95% CI 1.01-1.01; p < 0.001) were also independently associated with all-cause mortality, whereas female sex was associated with a significantly decreased risk (HR 0.69, 95% CI Nelson-Aalen cumulative hazard estimates curve for all-cause death in patients with active epilepsy stratified according to timevarying SRI status (patients were considered exposed after their second code for an SRI prescription). Epilepsia ILAE (Table S2) .
SRI exposure and possible seizure-related mortality The unadjusted incidence rate of possible seizure-specific mortality was roughly equivalent for those with epilepsy exposed to two or more SRI prescriptions (incidence rate = 0.0013 [13 deaths/9,766.8 person-years]) compared to those exposed to one or no SRI prescriptions (incidence rate = 0.0014 [138 deaths/95,877.3 person-years]).
Using a cause-specific Cox regression model, there was no significant difference in possible seizure-related mortality according to time-varying SRI exposure (HR 1.08, 95% CI 0.59-1.98; p = 0.80) in the epilepsy population, although female sex was protective (HR 0.70, 95% CI 0.50-0.96; p = 0.03; Table 4 ). The estimate was imprecise due to few outcomes. Likewise, using a competing risks model with a Firth correction, the hazard of a possible seizurerelated death within 6 months of prescription was not significantly elevated (HR 1.04, 95% CI 0.91-1.20; p = 0.51). Each 1-year increment increase in age was associated with an elevated risk of possible seizure-related death, as was each one point increase in CCI, and with worsening IMD. Female sex was, again, protective (Table S3) .
Bupropion exposure and mortality
We identified 15 patients (0.10%) patients who were exposed to two or more prescriptions for bupropion in the epilepsy cohort. The hazard of all-cause death was not significantly higher if exposed (HR 1.91, 95% CI 0.61-5.93; p = 0.26), although the overall estimate was imprecise due to the low number of outcomes (five deaths over 74.8 person-years in the bupropion group compared to 2,517 deaths over 105,569.3 person-years in the unexposed group). Insufficient numbers were available to evaluate the hazard of possible seizure-related mortality (0 possible seizurerelated deaths over 74.8 person-years in those exposed to two or more bupropion prescriptions compared to 151 possible seizure-related deaths over 105,569.3 person-years in those exposed to one or no bupropion prescription).
We identified 685 (0.42%) of 163,778, who received two bupropion prescriptions in the age, sex, and GP practicematched general population without epilepsy. Of those receiving two bupropion prescriptions, 296 (43%) had a code for current or past depression. Of interest, unlike the SRI analysis, the unadjusted mortality rate for those exposed to two or more bupropion prescriptions (incidence rate of all-cause death = 0.012 [43 deaths/3,599 personyears]) did not appear to differ substantially from those exposed to one or no prescription (incidence rate = 0.012 [14,480 deaths/1,193,242 person-years). However, bupropion is not approved for use as treatment for depression or anxiety in the United Kingdom (only for smoking cessation) and therefore we were concerned that there may be an age discrepancy between the two groups. Patients unexposed to two or more bupropion prescriptions were significantly older (median age 42; range 17-88) than those exposed (median age 40, range 18-69; p = 0.02), thus indicating a potential confounding protective effect. Indeed, when adjusting for age, the HR of death was twice that for the exposed compared to unexposed (HR 2.06, 95% CI 1.52-2.81; p < 0.001).
Similar to the SRI analyses, the adjusted hazard of allcause mortality (when controlling for age, sex, depression, CCI, and IMD) was significantly higher for those exposed to two or more bupropion prescriptions (HR 1.95, 95% CI 1.44-2.66; p < 0.001). Increasing age (HR 1.10 for each incremental year, 95% CI 1.09-1.10; p < 0.001), current or past depression (HR 1.19, 95% CI 1.15-1.24; p < 0.001), and increasing social deprivation (HR 1.01, 95% CI 1.01-1.01; p < 0.001) were all independently associated with allcause mortality. Conversely, female sex was associated with a significant protective effect (HR 0.70, 95% CI 0.67-0.73; p < 0.001).
Discussion
This study using large, linked data collected during routine care has paradoxically demonstrated that, contrary to evidence yielded from animal models, SRI use in patients with active epilepsy is associated with an elevated, rather than a decreased, risk of mortality. However, the risk appears generalizable to the overall population, as similar results were seen in age, sex, and GP practice-matched patients without epilepsy. This association appears common to antidepressants as a class, since consistent results were also obtained when substituting SRI use with bupropion, a nonserotonergic antidepressant. Furthermore, the risk associated with antidepressant use appears to result from a chronic, delayed process, rather than from an acute reaction, as the effect size is attenuated when evaluating SRI exposure and all-cause mortality during discrete 6-month epochs. Exposure to an SRI did not appear to significantly affect possible seizure-related death, although the analyses were limited by few outcomes.
Likely, the elevated risk of all-cause mortality related to SRI use is secondary to unmeasured clinical factors inherently associated with antidepressant use rather than through a direct drug effect. The subanalysis evaluating the risk over immediate 6-month intervals following drug prescription demonstrated an attenuated, rather than enhanced, risk, and the overall effect failed to reach significance in the general population. This is contrary to what would be expected if antidepressants were mechanistically responsible for premature death. Of interest, these results are consistent with a prior large prospective study that linked antidepressant use with an increased risk of sudden cardiac death over and above that conferred by depression alone. 25 Likewise, the protective effect of female sex was anticipated prior to the study. 26 The large statistical power conferred by CALIBER is one of the benefits of this platform. A randomized controlled trial of SRI use in epilepsy is impractical due to the attendant sample size. Assuming a risk of sudden death of 0.1% in an epilepsy population, with an a = 0.05 and a b = 0.2, one would require >100,000 patients for a well-powered randomized controlled trial. Thus small trials will inevitably lead to imprecise estimates that are of minimal clinical utility. Hence, large linked data such as these are useful for addressing potentially small, but clinically meaningful, associations. An additional strength is the use of a previously published EHR case definition for epilepsy that is 92% accurate for pediatric epilepsy. 15 This definition is anticipated to perform equally well in adult populations, an assertion that is corroborated by the fact that the proportion of patients meeting our case definition for epilepsy appears similar to that in the general UK population (0.6%), thus providing face validity. 27 Comparing the consistency between observed and expected incidence rates and prevalence proportions is a common means of validating cases derived from EHRs. 16 Requiring two codes for an SRI or bupropion on separate days enhanced the chances of an enduring prescription. It is not uncommon for antidepressants to be discontinued after a single prescription, often due to adverse effects, and therefore we imposed a stricter, more conservative, definition of exposure. However, irrespective of adherence, our results indicate that the very need for two SRI prescriptions is associated with an elevated risk of all-cause mortality in both those with and those without epilepsy. We treated exposure to an SRI or bupropion as a time-varying covariate in the primary analysis to minimize the risk of immortal time bias. 28 Finally, the secondary analysis (in which we stratified follow-up into discrete 6-month epochs) allowed us to further explore the immediate relationship between antidepressant exposure and mortality. Despite this, the results are subject to certain limitations. Misclassification bias may exist from the case definition for epilepsy. Although it is 92% accurate, 15 it was not designed for adults and we cannot exclude false-positive diagnoses of epilepsy. This bias is expected to be nondifferential in nature, though, thus diluting the magnitude of the overall estimate. Furthermore, there may be incomplete adjusting for depression status. Psychiatric symptoms and disorders are known to be underascertained in large population-based records such as administrative data, 29 and we were unable to control for conditions other than depression (e.g., bipolar disorder, schizophrenia). However, we were able to use a previously published case definition of depression designed for the CALIBER database, 17 and it was reassuring to note that 72% of the active seizure group and 74% of the control group who were exposed to two or more SRI prescriptions had a corresponding code for past or current depression. Further reassurance is provided by the fact that the demographic differences between those exposed and unexposed to SRIs (Table 1 ) differed in directions anticipated by clinical experience (e.g., higher rates of depression, comorbidities, and lower socioeconomic status). Unmeasured confounders are always an issue in nonrandomized studies. For instance, worse IMD was an independent risk factor for death. This could partially relate to medication nonadherence, 30 while lower socioeconomic status has been linked to both depression and early mortality. 31 There is minimal chance of misclassification of all-cause mortality. However, the fidelity of coding for cause-specific death may not be entirely accurate. In particular, seizure-related death may be inaccurately or simply undercoded. 32, 33 Therefore, we made the a priori decision to expand the definition to include the CALIBER codes for sudden death and ICD-9/10 codes for unknown/unspecified death (Appendix S1). This was predicated on the fact that a cardiovascular etiology is often the default assumed cause of death in otherwise healthy people with epilepsy. 34, 35 The obvious trade-off is that this approach may have inadvertently led to false-positive possible seizure-related deaths. Here, if SRI use had a deleterious effect on sudden cardiac death, this may have drowned out any putative protective effect on possible seizure-related death. However, there is evidence that epilepsy is a risk factor for sudden cardiac death in the general population 36 and yet epilepsy or seizures is often omitted as a proximate cause of death. 34 Thus it is important to include these codes both to limit false negatives and to evaluate any potential relationship whereby mitigating seizure frequency or severity through SRI use could have a positive downstream effect on sudden cardiac death. Furthermore, although there is a risk that this definition could have diluted the effect size, the overall number of outcomes (n = 151) was still low, leading to an imprecise result. It also must be noted that even in this large cohort, the potential effect of SRI use on seizure-specific mortality may be obscured by random error. Finally, we were unable to precisely determine whether there was a differential effect between antidepressant classes on possible seizure-related mortality in patients with epilepsy due to the low numbers exposed to bupropion. This almost certainly relates to the reluctance to use this medication in those with epilepsy due to its propensity to lower the seizure threshold. 37 Ultimately, analyses such as these are hypothesis generating and help inform future endeavors. This study cannot be used to establish a cause-effect relationship due to the intrinsic study design and source of data. Prospective studies are required to establish temporality. Furthermore, we cannot ensure adherence to SRIs or bupropion, cannot ensure the prescriptions were filled, and cannot determine the daily dose for each patient. Thus it is not possible to comment on a biologic gradient. Additional studies replicating these results would also be required to meet causal criteria. Finally, although intriguing, it is hard to argue for biologic plausibility of direct death related to antidepressant use. Rather, it is more credible that antidepressants function as a marker for an underlying biologic process that is not controlled for even when adjusting for age, sex, CCI attribution of comorbidities, and social deprivation according to the IMD.
This study provides important data that are directly applicable to both clinical practice and future research. Our results indicate that patients requiring multiple antidepressant prescriptions, even those without epilepsy, need to be followed closely as they represent a vulnerable population at increased risk of premature death. Vigilance may be required even for those who are seizure free, since it could potentially have a beneficial effect on all-cause mortality. Significantly, SRI was not related to seizure-related mortality, thus further alleviating fears that SRI use may be detrimental for seizures. However, the low number of possible seizure-specific outcomes and the attendant wide confidence intervals necessarily temper any conclusion about a protective effect. Future research designed to further elaborate on this association is crucial. Finally, an RCT of SRIs for the prevention of seizure-related death in patients with epilepsy appears impractical. Using increasingly large, linked EHR datasets, or systematically collected clinical data from multicenter cohorts can offer a valuable solution to further our understanding of SRIs, mortality, and prevention of seizure-related deaths. By quadrupling the sample size, we can halve the 95% CIs around the effect estimate. Hence, to obtain more precise measures of the overall effect of SRI use on possible seizure-related mortality, any future large, linked electronic and administrative health record datasets would require at least 65,000 patients with epilepsy. Therefore, concerted, multicenter efforts are required to address this critical issue.
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